Cohance Lifesciences Limited is a Healthcare company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹17,211 crore. The company reports a net profit margin of 5%. Revenue grew -23.1% year-over-year. Promoter holding stands at 64%, with FII participation at 22.9%.
Buying pressure is building (RSI/MACD momentum confirmed). More buyers than usual are participating (volume expansion above average). A trend-following indicator is on the bullish side (SuperTrend signal: buy). Most stocks in the same industry are struggling (sector — most peers below EMA20). The uptrend is visible even on the weekly chart (longer-term trend confirmed). The overall market is in a downtrend — all trades carry higher risk right now (BEAR MARKET regime, reduced confidence). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Early convergence forming: 3 signals are starting to align; watch for confirmation from the remaining signals before adding full position size.
Cohance Lifesciences Limited scores 60/100 (Positive Research Signal). The strongest signals are Trend (14/100) and Momentum (13/100). The weakest dimension is Growth (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.